Bain, Cinven buy Lonza Specialty Ingredients in $4.7 billion deal

▴ Bain, Cinven buy Lonza Specialty Ingredients in $4.7 billion deal
Lonza’s shares rose more than 60% last year, as it expanded in drugs and prepared to unload Specialty Ingredients.

Bain Capital and Cinven are acquiring Lonza’s Specialty Ingredients division in a deal worth $4.7 billion, the Swiss contract drugmaker said on Monday, as it focuses on its faster-growing unit that supplies drug and biotech companies.

The Bain-Cinven consortium had been listed with Germany’s Lanxess and buyout groups Advent, Carlyle and others as bidders for the unit that makes anti-dandruff shampoo ingredients, nutritional supplements for swine and microbial controls for wood and hygiene products.

Lonza, which said the enterprise value of the transaction is 4.2 billion Swiss francs ($4.7 billion), is doubling down on its accelerating drug business. Its customers include Moderna, which Lonza supplies with ingredients for its COVID-19 vaccine, and AstraZeneca, which hired the Swiss company to help make its COVID-19 antibody treatment.

“The sale of the Specialty Ingredients business will allow Lonza to focus on its position as a leading partner to the healthcare industry,” said Chairman Albert Baehny in a statement.

“The free cash flows resulting from the sale will allow us to accelerate our strategic priorities,” he added.

Lonza’s shares rose more than 60% last year, as it expanded in drugs and prepared to unload Specialty Ingredients.

The unit, once Lonza’s mainstay before the ascendant drugs and biotech division relegated it to the back burner, saw revenue fall 2.1% last year to 1.7 billion francs last year.

By contrast, Lonza’s drug, biotech and nutrition revenue rose 7.2% to 4.5 billion francs as Lonza pushed ahead with a big expansion, including building four new production lines for Moderna’s vaccine against the new coronavirus in the United States and in Switzerland.

Tags : #Lonza #LonzaSpecialityIngredients #Bain #Cinven #Carlyle #BainCapital #Advent #Moderna #AstraZeneca

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Fighting back against superbugs- A joint initiative by UK and India ResearchersMay 23, 2025
Archish Fertility & IVF Launches #RainbowBaby Campaign to Raise Miscarriage Awareness and Inspire HopeMay 22, 2025
Asian Hospital, Faridabad Becomes the First in the City to Launch Total Lab Automation with QuidelOrthoMay 22, 2025
Sharda Care Healthcity appoints Dr. Chirag Tandon as Director of Internal MedicineMay 22, 2025
Global Milestone in the Field of Robotic SurgeryMay 22, 2025
Medanta conducts advanced first aid training for Gurugram Traffic PoliceMay 22, 2025
When to Consult a Fertility Expert: Not Just After MarriageMay 22, 2025
Ovulation Tracking: A Doctor’s Guide to Doing It RightMay 22, 2025
Debunking IVF Myths: What Doctors SayMay 22, 2025
Aster CMI Hospital Becomes India’s Largest Pediatric Liver Transplant Program Under Affordable Transplant InitiativeMay 21, 2025
Point-of-care health technologies make a difference when deployed at point-of-needMay 21, 2025
Remidio Launches its new device ‘Pristine’, Innovating AI-Powered Eye Diagnostics with Dual Brand Strategy May 21, 2025
HCGMCC & SunAct Launch North Maharashtra’s 1st Centre Of Excellence In Cell & Gene TherapyMay 21, 2025
Transforming dementia support through technology networkMay 21, 2025
Endometriosis: The Pain You Shouldn’t IgnoreMay 21, 2025
The Best Age to Freeze Your Eggs — Doctor’s AdviceMay 21, 2025
Managing PCOS Without Birth Control: Fact or Fiction?May 21, 2025
Hormonal Acne in Women: It’s Not Just CosmeticMay 21, 2025
Is Spotting Between Periods Normal?May 21, 2025
QNET India Launches #BuzzForEarth Campaign on World Bee DayMay 20, 2025